A five-year study in the Journal of the American Medical Association found that neonatal caffeine treatment for apnea of prematurity did not improve survival without disability. The caffeine group and the placebo group did not differ in terms of mortality rate, behavior problems, motor impairment, poor general health, blindness or deafness, researchers reported.

Related Summaries